TAGAMET
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET is an oral solution small-molecule drug approved in 1977 by GSK. The generic name and specific indications are not provided in available data, but this is a legacy oral formulation product. As a mature NDA with approaching loss of exclusivity, it represents a foundational pharmaceutical asset.
LOE Approaching
As LOE approaches with moderate competitive pressure (30%), brand teams are typically in defensive or transition mode with downsizing or strategic repositioning activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate limited active hiring for this legacy product. Career growth on TAGAMET is constrained; professionals typically use LOE-stage assignments as stepping stones to growth-stage brands or specialized roles in generic/authorized generic strategy.
Brand ManagerField Sales Representative
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.